- Home
- ELUT vs ESLA Comparison
ELUT vs ESLA Comparison
Compare ELUT & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELUT | ESLA |
|---|---|---|
| Founded | 2015 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.9M | 45.6M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ELUT | ESLA |
|---|---|---|
| Price | $0.99 | $0.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 73.4K | 36.6K |
| Earning Date | 05-08-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,293,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.83 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $0.78 |
| 52 Week High | $2.50 | $3.15 |
Technical Indicators
Market Signals| Indicator | ELUT | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 47.35 | 45.12 |
| Support Level | $0.86 | $0.97 |
| Resistance Level | $0.99 | $1.31 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 44.44 | 42.96 |
Price Performance
Historical ComparisonAbout ELUT Elutia Inc.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.